Insider Trading Alert - KMG, ATSG And AGIO Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 16, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $442.00 to $2,999,379.00.

Highlighted Stocks Traded by Insiders:

KMG Chemicals (KMG) - FREE Research Report

Hatcher David L, who is 10% Owner at KMG Chemicals, sold 3,000 shares at $29.29 on June 16, 2015. Following this transaction, the 10% Owner owned 1.9 million shares meaning that the stake was reduced by 0.15% with the 3,000-share transaction.

The shares most recently traded at $29.05, down $0.23, or 0.81% since the insider transaction. Historical insider transactions for KMG Chemicals go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 24,000
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 70,500
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 75,500

The average volume for KMG Chemicals has been 86,500 shares per day over the past 30 days. KMG Chemicals has a market cap of $345.2 million and is part of the basic materials sector and chemicals industry. Shares are up 47.7% year-to-date as of the close of trading on Tuesday.

KMG Chemicals, Inc., through its subsidiaries, engages in the manufacture, formulation, and distribution of specialty chemicals in the United States, Mexico, Canada, Europe, Israel, and Singapore. It operates in two segments, Electronic Chemicals and Wood Treating Chemicals. The stock currently has a dividend yield of 0.41%. The company has a P/E ratio of 44.1. Currently, there is 1 analyst who rates KMG Chemicals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KMG - FREE

TheStreet Quant Ratings rates KMG Chemicals as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full KMG Chemicals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Air Transport Services Group (ATSG) - FREE Research Report

Manibusan Dennis A, who is Subsidiary President - ATI at Air Transport Services Group, sold 4,671 shares at $10.49 on June 16, 2015. Following this transaction, the Subsidiary President - ATI owned 48,061 shares meaning that the stake was reduced by 8.86% with the 4,671-share transaction.

The shares most recently traded at $10.21, down $0.28, or 2.74% since the insider transaction. Historical insider transactions for Air Transport Services Group go as follows:

  • 4-Week # shares sold: 4,671
  • 12-Week # shares sold: 34,765
  • 24-Week # shares sold: 54,765

The average volume for Air Transport Services Group has been 282,300 shares per day over the past 30 days. Air Transport Services Group has a market cap of $675.2 million and is part of the services sector and transportation industry. Shares are up 20.91% year-to-date as of the close of trading on Tuesday.

Air Transport Services Group, Inc., through its subsidiaries, provides airline operations, aircraft leasing and maintenance, and other support services primarily to the air cargo transportation and package delivery industries in the United States and internationally. The company has a P/E ratio of 19.5. Currently, there are 3 analysts who rate Air Transport Services Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATSG - FREE

TheStreet Quant Ratings rates Air Transport Services Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Air Transport Services Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Agios Pharmaceuticals (AGIO) - FREE Research Report

Higgons John Duncan, who is Chief Operating Officer at Agios Pharmaceuticals, sold 7,000 shares at $105.23 on June 16, 2015. Following this transaction, the Chief Operating Officer owned 121,835 shares meaning that the stake was reduced by 5.43% with the 7,000-share transaction.

The shares most recently traded at $102.96, down $2.27, or 2.2% since the insider transaction. Historical insider transactions for Agios Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,806
  • 4-Week # shares sold: 5,500
  • 12-Week # shares bought: 1,806
  • 12-Week # shares sold: 34,056
  • 24-Week # shares bought: 1,806
  • 24-Week # shares sold: 65,056

The average volume for Agios Pharmaceuticals has been 673,300 shares per day over the past 30 days. Agios Pharmaceuticals has a market cap of $3.9 billion and is part of the health care sector and drugs industry. Shares are down 6.95% year-to-date as of the close of trading on Tuesday.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. Currently, there are 2 analysts who rate Agios Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AGIO - FREE

TheStreet Quant Ratings rates Agios Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been the company's poor growth in earnings per share. Get the full Agios Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Facebook, Apple and Alphabet Are Actually Cheap Here, Jim Cramer Says

Facebook, Apple and Alphabet Are Actually Cheap Here, Jim Cramer Says

The Stock Market Isn't Stupid High: Market Recon

The Stock Market Isn't Stupid High: Market Recon

Insider Trading Alert - KMG, FSIC And HA Traded By Insiders

Insider Trading Alert - KMG, FSIC And HA Traded By Insiders

Insider Trading Alert - KMG, TCPC And WDC Traded By Insiders

Insider Trading Alert - KMG, TCPC And WDC Traded By Insiders

Insider Trading Alert - KMG, EGP, And MUX Traded By Insiders

Insider Trading Alert - KMG, EGP, And MUX Traded By Insiders